scispace - formally typeset
Journal ArticleDOI

Cis-diamminedichloroplatinum (II): A New Anticancer Drug

Marcel Rozencweig, +3 more
- 01 Jun 1977 - 
- Vol. 86, Iss: 6, pp 803-812
Reads0
Chats0
TLDR
Gastrointestinal, renal, audiologic, and relatively minor hematologic toxicities may be encountered, but promising methods have been developed to increase the therapeutic index of DDP.
Abstract
Cis-diamminedichloroplatinum (II) (DDP) leads the series of platinum coordination complexes, a new class of cytotoxic agents. The antitumor and toxic effects of this drug are discussed. It has displayed encouraging results in testicular tumors. The drug's therapeutic effectiveness has also been recognized in a variety of other solid tumors, particularly ovarian, bladder, and head and neck malignancies. Gastrointestinal, renal, audiologic, and relatively minor hematologic toxicities may be encountered, but promising methods have been developed to increase the therapeutic index of DDP.

read more

Citations
More filters
Journal ArticleDOI

Cisplatin: The first metal based anticancer drug.

TL;DR: This article highlights a systematic description on cisplatin which includes a brief history, synthesis, action mechanism, resistance, uses, side effects and modulation of side effects.
Journal ArticleDOI

Synthetic Methods for the Preparation of Platinum Anticancer Complexes

TL;DR: The demonstration in the 1960's that cis-diamminedichloroplatinum(II), or cisplatin, inhibits cellular division of Escherichia coli1 led to the subsequent discovery that this simple coordination compound is also an effective antitumor agent in mouse models.
Journal ArticleDOI

Intraperitoneal Cisplatin with Systemic Thiosulfate Protection

TL;DR: Regression of intraperitoneal tumor masses was observed in patients with far-advanced ovarian carcinoma, mesothelioma, and malignant carcinoid, and even at doses up to 270 mg/m2, no local toxicity occurred.
Journal ArticleDOI

Platinum complexes as anticancer agents

TL;DR: This review focuses on recent advances in developing platinum anticancer agents with an emphasis on platinum coordination complexes, which exhibit promising pharmacological properties.
Journal ArticleDOI

Cisplatin (cis-diamminedichloroplatinum II).

TL;DR: Cisplatin is a co-ordination complex of a central platinum atom, two chlordies and two ammonia molecules in the "cis" position that is a prime mechanism of inhibition of tumor growth by cisplatin appears to be inhibition of DNA synthesis.
References
More filters
Journal ArticleDOI

Platinum Compounds: a New Class of Potent Antitumour Agents

TL;DR: The platinum compounds inhibit sarcoma 180 and leukaemia L1210 in mice and reversibly inhibit cell division in Gram-negative rods1–4.
Journal ArticleDOI

Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode

TL;DR: In E. coli, the presence of certain group VIIIb transition metal compounds in concentrations of about 1–10 parts per million of the metal in the culture medium causes an inhibition of the cell division process, which implies that the growth process is not markedly affected.
Journal Article

Clinical and pharmacological studies with cis-diamminedichloroplatinum (II).

TL;DR: Renal impairment was the dose-limiting toxicity in the single-dose escalation scheme used, and progressive renal failure contributed to the death of one patient, this Phase I investigation characterizes the toxicity and pharmacological disposition of the drug in 10 patients.
Journal ArticleDOI

Phase II evaluation of adriamycin in human neoplasia.

TL;DR: It is concluded that adriamycin is an active agent, most remissions occur promptly, and significant cardiotoxic reactions appear to be cumulative.
Journal ArticleDOI

The Inhibition of Growth or Cell Division in Escherichia coli by Different Ionic Species of Platinum(IV) Complexes

TL;DR: The cis and trans forms of the diamino complex, [PtCl4(NH3)2]0, have been synthesized and the electrophoretic patterns indicate predominantly neutral species in both cases.
Related Papers (5)